|Application ||WB, IF|
|Other Accession||P70645, P13019, Q8R016|
|Calculated MW||H=53;M=53;Rat=52 KDa|
|Other Names||BLMH;Bleomycin hydrolase|
|Target/Specificity||This BLMH antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 212-242 amino acids from the Central region of human BLMH.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||BLMH Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||The normal physiological role of BLM hydrolase is unknown, but it catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by hydrolyzing the carboxamide bond of its B- aminoalaninamide moiety thus protecting normal and malignant cells from BLM toxicity.|
The normal physiological role of BLM hydrolase is unknown, but it catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by hydrolyzing the carboxamide bond of its B-aminoalaninamide moiety thus protecting normal and malignant cells from BLM toxicity (By similarity).
Barrow I.K.-P., et al. Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
Ferrando A.A., et al. Cancer Res. 56:1746-1750(1996).
Broemme D., et al. Biochemistry 35:6706-6714(1996).
Kalnine N., et al. Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
Ota T., et al. Nat. Genet. 36:40-45(2004).